shutterstock_619031537_castleski-1

Castleski / Shutterstock.com

23 June 2021Big PharmaAlex Baldwin

Pharma company fails to block €140m licence payment

Taiwanese pharmaceutical company PharmaEssentia Corporation (PEC) has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals (AOP).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

More on this story

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

More on this story

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility